TY - JOUR T1 - Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052). JO - European Journal of Cancer PY - 2013/06/24 AU - O'Brien ME AU - Gafaar RM AU - Popat S AU - Grossi F AU - Price A AU - Talbot DC AU - Cufer T AU - Ottensmeier C AU - Danson S AU - Pallis A AU - Hasan B et al ED - DO - DOI: 10.1016/j.ejca.2013.05.008 Y2 - 2025/08/20 ER -